Business Development

Collaborative Drug Discovery

Cyclenium offers partners for their own targets access to its proprietary CMRT drug discovery technology and QUEST Library, hit generation, and extensive expertise in optimization to clinical candidates. In addition:

  • Design and construction of targeted libraries based on peptide leads or known target-ligand interactions
  • Creation of custom-designed macrocycles for addition to corporate screening collections
  • Process research and development support for macrocycle scale-up and manufacturing
  • Customer-focused design of macrocycle-based R&D programs


Cyclenium is seeking partners with interest in the development of its advanced lead programs:

  • Broad spectrum anti-flaviviral agents
  • Novel target strategy for the treatment of cystic fibrosis
  • Biased signaling opioid receptor agonists for the targeted therapy of PTSD and anxiety disorders

For additional information please contact our parent company, SpiroChem.


Cyclenium also welcomes inquiries from researchers with interesting early-stage discovery and development opportunities, particularly in the fields of oncology, anti-infectives, inflammation and pain.

Please contact our parent company, SpiroChem, for further discussions.